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The increasing prevalence of dementia already has dr matic effects on lives of millions of 
people across the regions and on public health costs. There is no cure yet but much can be 
done to improve the quality of life of people with dementia and the families who care for 
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them. An extensive review of the literature in several pertin nt areas of inquiry that may 
determine and delineate the prevalence, potential risk factors related to dementia was 
undertaken. The overall prevalence for males and females doubled for every five years 
increase in age after the age of 65. It is largely a disease of older people, but 2% of those 
affected were under 65 years of age. Results highlight a number of risk factors associated with 
dementia. Inter alia, these include physical activities, education, occupation, stress, 
cholesterol and APOE gene. Dementia is increased in certain population and the trend is on 
the rise. A number of risk factors associated with dementia are modifiable and may have 
potential as strategies useful in preventing or delaying dementia among elderly subjects. 
Further research is needed to determine the validity and strength of associations of risk factors 
of dementia including ascertainment of its causality. 
 




Dementia is a clinical syndrome under the umbrella term neurodegenerative disease. Inter 
alia, this term includes other diseases such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease, Multiple Sclerosis (MS) 
and Autistic spectrum disorders (ASD). Dementia is characterized by a decline in cognitive 
functions without impairment in consciousness. It is a non-specific illness characterized by 
cluster of symptoms and signs manifested by difficulties in memory, attention, language, and 
problem solving beyond what might be expected from normal aging. Although it is far more 
common in the geriatric population, it may occur in any stage of adulthood. It is global health 
and social crisis (Boustani et al., 2003). 
Although there are more than 70 diseases that cause dem ntia, Alzheimer’ disease (AD) is the 
most common cause and accounts for 50-70% of dementia, a d combination of Alzheimer’s 
disease and vascular dementia account for between 80-90% of cases (Black et al., 2001). It is 
a brain disorder usually in elderly, associated with slow progressive loss of brain function 
notably lapses in memory, disorientation, confusion, mood swings, changes in personality, 
language problems, such as difficulty in finding the right words for everyday objects, loss of 
behavioral inhibitions, loss of motivation and paranoi . Other subtypes of dementia are 
vascular dementia associated with vascular risk factors (Hachinski et al., 2006), lewy body 
dementia associated with eosinophilic cytoplasmic inclusion (Wild et al., 2003) 
frontotemporal dementia most commonly caused by frontotemporal degeneration (Rosen et 
al., 2002) and mixed dementia a combination of Alzheimer’s disease and vascular dementia 
(Zekry et al., 2002). 
Clinical features of dementia may be described in terms of as cognitive which includes 
impaired memory (most prominent early symptom), loss of previously learnt material, 
language affectation and poor judgment and non-cognitive which includes verbal or physical 
agitation, aggressive and non-aggressive behaviour, depression (most common), sleep 
disturbances and psychosomatic symptoms (Clinical practice guideline, 2009). 
Dementia simulates delirium and depression and these ave to be differentiated (MacIntosh 
and Woodall, 1995). Symptoms of sleep apnea have also been reported to be associated with 
cognitive impairment in dementia (Ancoli-Israel and Coy, 1994). Patients with severe 
dementia were found to have severe obstructive sleep apnea, and those with severe 
obstructive sleep apnea had severe dementia (Clinical practice guideline, 2009). 
Fortunately, there are some warning signs of dementia that one can look out carefully and 
take certain steps to reduce the risk of dementia. The warning signs are: memory loss that 
affects day-to-day performance, difficulty in doing familiar tasks, confusion about time and 
place, problems in communication, difficulty in planning or solving problems, poor judgment, 
misplacing things, changes in mood, changes in behaviour, changes in personality, 
withdrawal from work, cessation of social networking. 
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Notwithstanding, anyone may experience similar situat ons from time to time. The difference 
with dementia is that these characteristics will progressively get worse and affects 




Articles and/or pertinent documents included in this review were primarily identified through 
a Google Scholar search of the terms dementia, prevalence, incidence, risk factors and cause. 
Inter alia, studies retained for reviews were generally limited to empirical investigations that 
provided data related to prevalence, incidence, risk factors and definitional criteria for the 




Prevalence of Dementia:  
 
The world wide current prevalence of dementia was estimated to be 30 million people, with 
4.6 million people affected annually which gave an estimate of about one case in every 7 
seconds. The number of people affected was predicted to be over 100 million by 2050 (Wimo 
et al., 2003; Alzheimer’s disease International, 2008) with an expectation to be double every 
20 years (Ferri et al., 2005). Based on the studies in developed countries, the overall 
prevalence for males and females doubled for every five years increase in age after the age of 
65. It is largely a disease of older people, but 2% of those affected were under 65 years of age 
(Table 1).  
 
Table 1: Incidence and prevalence rates of dementia from the EURODEM meta-analyses for 
    European studies (source: Alzheimer’s disease international 2008) 
 
Age group Annual incidence per 100 Prevalence % 
 Males Females Males Females 
60-64 0.2 0.2 0.4 0.4 
65-69 0.2 0.3 1.6 1.0 
70-74 0.6 0.5 2.9 3.1 
75-79 1.4 1.8 5.6 6.0 
80-84 2.8 3.4 11.0 12.6 
85-89 3.9 5.4 12.8 20.2 
90+ 4.0 8.2 22.1 30.8 
 
 
ADI commissioned a panel of experts reached a consensu  estimate of prevalence in each 
world region (Wimo et al., 2003; Alzheimer’s diseas International, 2009). The trend of for a 
lower prevalence of dementia in developing countries as opposed to developed countries was 
also supported by the consensus judgment of the exprt panel (Table 2).  
 
Table 2: ADI consensus estimates for the prevalence of dementia (%), by WHO region and    










75-79 80-84 85+ 
EURO (A) W Europe 0.9 1.5 3.6 6.0 12.2 24.8 
EURO (B) E Europe 0.9 1.3 3.2 5.8 12.2 24.7 
EURO (C) E Europe 0.9 1.3 3.2 5.8 11.8 24.5 
AMRO (A) N America 0.8 1.7 3.3 6.5 12.8 30.1 
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AMRO (D) S America 0.8 1.7 3.4 7.6 14.8 33.2 
AMRO (C) S America 0.7 1.5 2.8 6.2 11.1 28.1 
EMRO (B) Middle East 0.9 1.8 3.5 6.6 13.6 25.5 
EMRO (D) N Africa, Middle East 1.2 1.9 3.9 6.6 13.9 23.5 
WPRO (A) Japan, Australia, NZ 0.6 1.4 2.6 4.7 10.4 22.1 
WPRO (B) China and neighbours 0.6 1.7 3.7 7.0 14.4 26.2 
SEARO (B) Indonesia, SL, 
Thailand 
1.0 1.7 3.4 5.7 10.8 17.6 
SEARO (D) India and neighbours 0.4 0.9 1.8 3.7 7.2 14.4 
AFRO (D) Sub-Saharan Africa 0.3 0.6 1.3 2.3 4.3 9.7 
AFRO (E) Sub-Saharan Africa 0.5 1.0 1.9 3.8 7.0 14.9 
 
Note: A (lowest) to E (highest) are subgroups of the WHO world regions based on patterns of 
child and adult mortality. 
It is evident that dementia already has dramatic effects on lives of millions of people across 
the region and on public health costs. There is no cure yet but much can be done to improve 
the quality of life of people with dementia and thefamilies who care for them. The key is to 
recognize dementia as a priority health problem and in oing so, to plan the action to be 
taken. It is also important to promote collaboration in terms of research, data exchange which 
would be useful to draw the attention of governments, international organizations, and aid 
agencies to the dementia epidemic and the threat that it posed to public health system. It 
would be useful too in the development of effective health care services for people with 
dementia and families who care for them. The number of new cases of dementia in Asia 
Pacific region was projected to increase 4.3 million new cases per year in 2005 to 19.7 million 
new cases by 2050. The proportion of people with dementia was expected to increase from 
0.38% of the total regional population to 1.4% over the next 45 years. Individual country data 
for the estimated old and new cases of dementia are summarized in the table below (Dementia 
in the Asia Pacific Region: The Epidemic is Here 2006; Alzheimer’s Australia 2006; Kow, 
2009).  
 
Table 3: Estimated prevalence and incidence of dementia by the selected country and the year 
in Asia Pacific Region 
 
2005 2020 2050  
‘000 people 
Prevalence Incidence Prevalence Incidence Prevalence Incidence 
Australia 195.4 60.2 301.3 91.1 664.1 199.7 
China 5,541.2 1,721.0 9,596.3 2,916.7 27,004.4 8,269.0 
India  3,248.5 1.026.8 5,541.8 1.714.4 16,290.1 4,974.6 
Indonesia 606.1 191.4 1,016.8 314.1 3,042.0 932.0 
Japan 1,871.2 570.2 3,251.3 983.4 4,873.1 1,4517.7 
Malaysia 63.0 20.1 126.8 39.0 453.9 138.8 
Pakistan 330.1 107.3 566.6 179.3 1,916.2 584.3 
Philippines 169.8 54.8 316.3 99.2 1,158.9 353.9 
Singapore 22.0 6.8 52.6 15.7 186.9 56.7 
Thailand 229.1 71.4 450.2 137.2 1,233.2 377.0 
 
It appears from Table 3 that in Malaysia, the prevalence of dementia was estimated to be 
63,000 people in 2005 with annual incidence cases of 20,100. This number was projected to 
be 126,800, annual new cases of 39,000 by 2020 and 453,900, annual new cases of 138,800 
(Alzheimer’s disease International, 2006). Different small scale studies give slightly different 
results depending on their methodologies. But the dementia epidemic is a certainty (Table 4).  
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Table 4: Prevalence of dementia among elderly population in Malaysia 
 
Title and Location Year Sample size Prevalence % 
Prevalence of undetected cognitive 
impairment and depression in 
residents of an elderly care home 
Kedah Darul 
Aman 
2007 167 36.5 
Proportion of dementia and its 
associated factors among elderly 
patients attending outpatient clinics 
of Unversiti Sains Malaysia 
Kubang 
Kerian 
2006 399 2.5 
The prevalence of depression 
among elderly in an urban area of 
Selangor, Malaysia  
Selangor 2005 25 8.3 
Prevalence of dementia among 
elderly Malays in an urban 
settlement in Malaysia 
Kuala 
Lumpur 
2006 323 6.0 
Cognitive impairment among the 




2004 223 22.4 
 
Risk Factors:  
 
The risk factors of dementia maybe divided into two categories: non-modifiable and 
modifiable. Of the studied non-modifiable risk factors, age is the best-studied and strongest 
risk factor for dementia. Other non-modifiable risk factors include gender (more in females), 
genetic e.g., having a first-degree relative with a history of dementia and having the 
apolipoprotein E4 genotype (Boustani et al., 2003).  
There are 3 causative gene mutations of dementia. These are β-amyloid protein precursor 
(AβPP) which is located chromosome 21, presenilline 1 (PS1) located on chromosome 14 and 
preseniline 2 (PS2) located on chromosome 1. 30-70% mutations are in PS1, 10-15 % in 
AβPP and 5% in PS2 (Patterson et al., 2008). No single genetic causation of dementia has 
been identified; most are complex influences of genetic risk factors. For instance, 
apolipoprotein E (ApoE), sortilin-related receptor 1 gene (SORL1) and environmental factors 
in combination gives Alzheimer’s disease. Apo Eε4 is the only established single risk factor 
of late onset dementia (Li and Grupe, 2007). Apolipoprotein CI (apoCI) and low density 
lipoprotein (LDL) receptors have also been reported o modulate individuals risk to 
developing dementia (Retz et al., 2001). 
Product of ApoE gene is a class of lipoprotein (apoE), 299 amino acids long, found in the 
chylomicron and intermediate density lipoproteins (IDLs) that binds to a specific receptor on 
liver cells and peripheral cells. It is essential for the normal catabolism of triglyceride-rich 
lipoprotein constituents (Entrez Gene, 2010). ApoE is essential for the normal catabolism of 
triglyceride-rich lipoprotein constituents. ApoE was initially recognized for its importance in 
lipoprotein metabolism and cardiovascular disease. More recently, it has been studied for its 
role in several biological processes not directly related to lipoprotein transport, including 
Alzheimer's disease (AD), immunoregulation, and cognition. Growing amount of studies 
point to apoE's interaction with many immunological processes, including suppressing T-cell 
proliferation, macrophage functioning regulation, lipid antigen presentation facilitation (by 
CD1) to natural killer T cell as well as modulation f inflammation and oxidation (Zhang et 
al., 2010). 
The ApoE gene is mapped to chromosome 19 in a cluster wi h apolipoprotein C1 and the 
apolipoprotein C2. The ApoE gene consists of four exons and three introns, totaling 3597 
base pairs. In melanocytic cells APOE gene expression may be regulated by Microphthalmia-
associated transcription factor (MITF) (Hoek et al., 2008). The normal gene is apoE-ε3 while 
the dysfunctional genes are apoE-ε2 and apoE-ε4. The ε2 allele has a Cys at positions 112 and 
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158 in the receptor-binding region of ApoE, the ε3 allele has Cys at 112 and Arg at 158 while 
the ApoE ε4 allele has Arg at both positions 112 and 158, andthese have physiological 
consequences (Ghebranious et al., 2005). ApoE-ε2 is associated with the genetic disorder 
hyperlipoproteinemia type III and with both increasd and decreased risk for atherosclerosis 
(Breslow et al., 1982). ApoE-ε3 is found in approximately 64 percent of the population, is 
considered to be a neutral Apo E genotype while apoE-ε4 has been implicated in 
atherosclerosis and Alzheimer's disease, impaired cognitive function, and reduced neurite 
outgrowth. The estimated human genotype frequencies ar  depicted in Table 5 (Hill et al., 
2007). 
 
Table 5. Estimated human genotype frequency of apoE  
 
Allele ε2 ε3 ε4 
ε2 ~1–2% ~15% ~1–2% 
ε3  ~55% ~25% 
ε4   ~1–2% 
 
The potentially modifiable risk factors of dementia include cardiovascular factors such as 
hypertension (National Clinical Practice Guideline, 2007), diabetes mellitus, 
hypercholesterolemia (Purnell et al., 2009), vitamin B12 and folic acid deficiency (Vogel et 
al., 2009). The life style related factors include i t (Whitmer et al., 2005). Evidence has 
suggested that regular physical exercise may prevent or delay the onset of dementia in older 
persons (Lin, 2006), such that the risk of developing dementia is higher in individuals who do 
not exercise. Smoking, obesity and alcohol consumption are also modifiable risk factors 
(National Clinical Practice Guideline, 2007). 
However, tt has been reported that 15% of people with dementia have a potentially treatable 
cause, but the prevalence of reversible dementia is only 1% (Walstra et al., 1997).  
 
Dementia risk score: 
 
A pragmatic tool for predicting the risk of dementia may be considered encompassing the 
easily measureable characteristics as appear in Table 6. 
 




64 - 84 1 
Age (in year)                      
≥ 84 2 
≥ 11 0 
6 – 10 1 
Education 
≤ 5 2 
Female 0 Gender 
Male 2 
Married 0 Marital status 
Unmarried 1 
Practice 0 Sex 
Don’t practice 1 
Religious 0 Religiosity 
Not religious 1 
Maintain 0 Social Network 
Not mantain 1 
Blood pressure Normal 0 




≤ 23 0 Body mass index (kg/m2) 
> 23 3 
≤ 6.2 0 Total cholesterol level 
> 6.2 3 
Active 0 Physical activity 
Inactive 1 
 
This risk score provide a quantitative assumption of the probability of becoming dementic but 
it can’t be used to state certainly whether a person will develop dementia (or not develop 
dementia). However, it can be used to identify the personnel who are at risk most and to 




Epidemiological studies of dementia among elderly people from developing countries are 
scarce. In this, the systematic review of the literature on dementia in the older people, 
surprisingly it was found only a few small scale studies that report the prevalence and 
predictors of dementia. Thus, although it seems likely, it cannot be shown with numbers 
and/or figures conclusively that dementia is increased in certain population and the trend is on 
the rise. Some reports delineated the scenario of dementia country-wise based on assumptive 
and administrative perspective with estimated projection of incidence and prevalence of 
dementia. On the other hand, the small scale studies, th  sample sizes were small and used 
screening instruments of uncertain cultural validity probably. The study with highest 
prevalence of dementia had the smaller number of study subjects, and the lowest prevalence 
had the highest sample size. The sampling technique and operational definition of dementia 
also differs from study to study that may have led to a erroneous estimation of the magnitude 
of prevalence of dementia. 
The association between dementia/cognitive impairment and lifestyle determinants including 
plausible biochemical markers and genetic risk factors were less clear and lack in most 
instances. Interestingly most important predictors of dementia such as hypertension, diabetes 




The increasing prevalence of dementia as the population ges will have a dramatic impact on 
both provision of health care and the economy in geeral. A number risk factors associated 
with dementia are modifiable and there are potential s r tegies for enabling either elderly 
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